OncoHealth Corporation, a Redwood City, CA-based developer of novel diagnostics for cervical cancer and other potentially deadly cancers caused by the human papillomavirus (HPV), has raised $1.6m in a Series A funding.
Investors include Sand Hill Angels and Life Science Angels.
The company intends to use the funds to participate in a comparative study currently being conducted by the federal government and a national reference laboratory to evaluate OncoHealth’s technology.
“Companies trying to raise between $1 million and $4 million increasingly encounter a funding gap. The amount is too big for a single angel group and too small for most venture capitalists,” said
Don Ross, Sand Hill Angels Board Director, Life Science Angels member, is also a OncoHealth’s Board Director.
Led by CEO Winnie Wan, Ph.D., OncoHealth plans to commercialize proprietary tests, which are designed to enable clinicians to triage HPV-infected patients based on their cancer-progression status and select the most effective treatments.